Julie Buford
Women's Health · Fredericktown, MONPI 1043490857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 45.4% of the total. Among women's health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$578
- Novo Nordisk$411
- Amgen$173
- Axsome Therapeutics, Inc.$118
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$116
- plus $1K from 29 others
What the payments were for
- Food & beverage$4,889100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 117 | $2,220 |
| Lilly USA, LLC | 37 | $578 |
| Novo Nordisk | 21 | $411 |
| Amgen | 9 | $173 |
| Axsome Therapeutics, Inc. | 5 | $118 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $116 |
| Supernus Pharmaceuticals, Inc. | 6 | $114 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $101 |
| Endo Pharmaceuticals Inc. | 5 | $92 |
| Amarin Pharma, Inc. | 6 | $83 |
| Exeltis, USA Inc. | 4 | $68 |
| Biohaven Pharmaceuticals, Inc. | 4 | $66 |
| Boehringer Ingelheim | 4 | $60 |
| AstraZeneca | 4 | $57 |
| Merck | 4 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Eisai Inc. | 3 | $41 |
| Ardelyx, Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| Exact Sciences | 2 | $37 |
| Pfizer | 2 | $28 |
| Electromed, Inc. | 2 | $28 |
| GSK | 1 | $23 |
| Apria Healthcare LLC | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Organon | 2 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
How this compares
$4,889 in reported general payments places this provider in the 90th percentile of 208 women's health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $37,214 |
| MounjaroTirzepatide | 23 | $23,841 |
| LinzessLinaclotide | 21 | $14,743 |
| OzempicSemaglutide | 14 | $13,293 |
| TrulicityDulaglutide | 11 | $9,743 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $6,566 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 30 | $2,244 |
| Omega-3 Acid Ethyl Esters | 18 | $1,523 |
| Potassium Chloride | 67 | $1,186 |
| Levothyroxine Sodium | 195 | $1,089 |
| Levocetirizine Dihydrochloride | 83 | $966 |
| Atorvastatin Calcium | 179 | $838 |
| Montelukast Sodium | 52 | $566 |
| Losartan Potassium | 83 | $552 |
| Omeprazole | 98 | $535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $23 | $37,21448 claims |
| Lilly USA, LLCMounjaro, Trulicity | $578 | $33,58434 claims |
| AbbVieLinzess | $2,220 | $14,74321 claims |
| Novo NordiskOzempic | $411 | $13,29314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 208 women's health providers in Missouri.
Other women's health in Fredericktown
- Kathryn SimoneBlue Springs$192K
- Nealya Bell-SilvaSaint Louis$107K
- Susan HoffstetterSaint Louis$39K
- Karla WilmotIndependence$22K
- Janice EislebenSaint Louis$16K
- Susan Mitchell-DerenskiSaint Louis$14K
- Amanda SchillySaint Louis$8K
- Jeanette ShanholtzerLees Summit$7K
- Kris ScalfSaint Louis$7K
- Savannah HayesSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.